YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation

Despite the promising clinical efficacy of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in patients with ALK-rearranged lung cancer, some tumor cells survive and eventually relapse, which may be an obstacle to achieving a cure. Limited information is currently available...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsuji, Takahiro, Ozasa, Hiroaki, Aoki, Wataru, Aburaya, Shunsuke, Yamamoto Funazo, Tomoko, Furugaki, Koh, Yoshimura, Yasushi, Yamazoe, Masatoshi, Ajimizu, Hitomi, Yasuda, Yuto, Nomizo, Takashi, Yoshida, Hironori, Sakamori, Yuichi, Wake, Hiroaki, Ueda, Mitsuyoshi, Kim, Young Hak, Hirai, Toyohiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6941996/
https://www.ncbi.nlm.nih.gov/pubmed/31900393
http://dx.doi.org/10.1038/s41467-019-13771-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6941996/
https://www.ncbi.nlm.nih.gov/pubmed/31900393
http://dx.doi.org/10.1038/s41467-019-13771-5

Ejemplares similares